These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12393095)

  • 41. Thyroid hormone-induced alterations in phospholamban-deficient mouse hearts.
    Kiss E; Brittsan AG; Edes I; Grupp IL; Grupp G; Kranias EG
    Circ Res; 1998 Sep; 83(6):608-13. PubMed ID: 9742056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition.
    Schmitt JP; Ahmad F; Lorenz K; Hein L; Schulz S; Asahi M; Maclennan DH; Seidman CE; Seidman JG; Lohse MJ
    Circulation; 2009 Jan; 119(3):436-44. PubMed ID: 19139388
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1.
    Pathak A; del Monte F; Zhao W; Schultz JE; Lorenz JN; Bodi I; Weiser D; Hahn H; Carr AN; Syed F; Mavila N; Jha L; Qian J; Marreez Y; Chen G; McGraw DW; Heist EK; Guerrero JL; DePaoli-Roach AA; Hajjar RJ; Kranias EG
    Circ Res; 2005 Apr; 96(7):756-66. PubMed ID: 15746443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure.
    Rupp H; Vetter R
    Br J Pharmacol; 2000 Dec; 131(8):1748-56. PubMed ID: 11139455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Calcium-binding of cardiac sarcoplasmic reticulum and diastolic hemodynamics in volume overloaded canine hearts.
    Maeba T
    Jpn Circ J; 1985 Feb; 49(2):163-70. PubMed ID: 3974123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sarcoplasmic reticulum Ca2+ refilling controls recovery from Ca2+-induced Ca2+ release refractoriness in heart muscle.
    Szentesi P; Pignier C; Egger M; Kranias EG; Niggli E
    Circ Res; 2004 Oct; 95(8):807-13. PubMed ID: 15388639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthases.
    Khan SA; Skaf MW; Harrison RW; Lee K; Minhas KM; Kumar A; Fradley M; Shoukas AA; Berkowitz DE; Hare JM
    Circ Res; 2003 Jun; 92(12):1322-9. PubMed ID: 12764022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of sarcoplasmic reticulum calcium loading on mechanical and relaxation restitution.
    Hoit BD; Kadambi VJ; Tramuta DA; Ball N; Kranias EG; Walsh RA
    Am J Physiol Heart Circ Physiol; 2000 Mar; 278(3):H958-63. PubMed ID: 10710365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulatory effects of phospholamban on cardiac function in intact mice.
    Lorenz JN; Kranias EG
    Am J Physiol; 1997 Dec; 273(6):H2826-31. PubMed ID: 9435620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis.
    Kiriazis H; Sato Y; Kadambi VJ; Schmidt AG; Gerst MJ; Hoit BD; Kranias EG
    Cardiovasc Res; 2002 Feb; 53(2):372-81. PubMed ID: 11827688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serine 16 phosphorylation induces an order-to-disorder transition in monomeric phospholamban.
    Metcalfe EE; Traaseth NJ; Veglia G
    Biochemistry; 2005 Mar; 44(11):4386-96. PubMed ID: 15766268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery.
    Hoshijima M; Ikeda Y; Iwanaga Y; Minamisawa S; Date MO; Gu Y; Iwatate M; Li M; Wang L; Wilson JM; Wang Y; Ross J; Chien KR
    Nat Med; 2002 Aug; 8(8):864-71. PubMed ID: 12134142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality.
    Dash R; Kadambi V; Schmidt AG; Tepe NM; Biniakiewicz D; Gerst MJ; Canning AM; Abraham WT; Hoit BD; Liggett SB; Lorenz JN; Dorn GW; Kranias EG
    Circulation; 2001 Feb; 103(6):889-96. PubMed ID: 11171800
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sarcoplasmic phospholamban protein is involved in the mechanisms of postresuscitation myocardial dysfunction and the cardioprotective effect of nitrite during resuscitation.
    Huang Y; He Q; Zhan L; Yang M
    PLoS One; 2013; 8(12):e82552. PubMed ID: 24386101
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transgenic approaches to define the functional role of dual site phospholamban phosphorylation.
    Luo W; Chu G; Sato Y; Zhou Z; Kadambi VJ; Kranias EG
    J Biol Chem; 1998 Feb; 273(8):4734-9. PubMed ID: 9468536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mouse phospholamban gene expression during development in vivo and in vitro.
    Ganim JR; Luo W; Ponniah S; Grupp I; Kim HW; Ferguson DG; Kadambi V; Neumann JC; Doetschman T; Kranias EG
    Circ Res; 1992 Nov; 71(5):1021-30. PubMed ID: 1394867
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phospholamban is present in endothelial cells and modulates endothelium-dependent relaxation. Evidence from phospholamban gene-ablated mice.
    Sutliff RL; Hoying JB; Kadambi VJ; Kranias EG; Paul RJ
    Circ Res; 1999 Feb; 84(3):360-4. PubMed ID: 10024311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phospholamban: a major determinant of the cardiac force-frequency relationship.
    Bluhm WF; Kranias EG; Dillmann WH; Meyer M
    Am J Physiol Heart Circ Physiol; 2000 Jan; 278(1):H249-55. PubMed ID: 10644605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure.
    Sanganalmath SK; Babick AP; Barta J; Kumamoto H; Takeda N; Dhalla NS
    J Cell Mol Med; 2008; 12(5A):1728-38. PubMed ID: 18088389
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human.
    Haghighi K; Kolokathis F; Pater L; Lynch RA; Asahi M; Gramolini AO; Fan GC; Tsiapras D; Hahn HS; Adamopoulos S; Liggett SB; Dorn GW; MacLennan DH; Kremastinos DT; Kranias EG
    J Clin Invest; 2003 Mar; 111(6):869-76. PubMed ID: 12639993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.